How can decentralized clinical trials improve patient access without adding unnecessary complexity? In a new BioPharm International article, Dr. Michael Murphy shares his perspective on why hybrid models are often the most practical approach and what sponsors need to consider around patient burden, data integrity, logistics, and oversight. Read the full article here.
